Clinical trials: Steroid-resistant Severe aGVHD
Steroid-resistant Severe aGVHD
MSC for Severe aGVHD
Steroid-resistant acute graft-versus-host disease (aGVHD) is one of the most severe complications in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), which cannot be significant benefit from the…
- Trial name
- NCT03631589
- Testing
- MSCs
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Graft Vs Host Disease
A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease
This is an academic open-label, phase II randomized study in patients with steroid resistant severe acute Graft versus host disease (GvHD) who have had allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT05132166
- Testing
- Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib., Decidual Stromal Cells
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Safety and Efficacy
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4 aGVHD is systemic glucocorticoid.
- Trial name
- NCT05021276
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Safety and Efficacy
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT06066840
- Testing
- Basiliximab, Vedolizumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
This phase I trial studies the side effects of using an investigational procedure (fecal microbiota transplantation [FMT]) in treating patients with severe acute gut graft-versus-host-disease.
- Conditions
- Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease, Severe Gastrointestinal Tract Acute Graft Versus Host Disease, Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease
- Trial name
- NCT04280471
- Testing
- Fecal Microbiota Transplantation Capsule
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center